Last edition
News about Drug Discovery & Development
AGC Biologics’ Milan Cell and Gene Centre of Excellence will support the commercial rollout of Waskyra following US FDA and EU approvals, strengthening treatment options for patients with Wiskott-Aldrich syndrome.
Drug Discovery & Development | 22/01/2026 | By News Bureau
CDSCO Flags 167 Drug Samples as Substandard, Seven Found Spurious
India’s drug regulator has identified 167 medicine samples that failed quality tests and classified seven additional samples as spurious during routine surveillance conducted in December. The findings were released as part of the Central Drugs Standard Control Organisation’s (CDSCO) monthly drug alert.
Drug Discovery & Development | 22/01/2026 | By Darshana
China's NMPA Accepts Akeso's Gumukimab sNDa for Ankylosing Spondylitis
China’s NMPA gives approval to Akeso’s gumokimab for the treatment of active ankylosing spondylitis, supported by Phase III data showing significant symptom relief and functional improvement.
Drug Discovery & Development | 20/01/2026 | By News Bureau
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
Drug Discovery & Development | 19/01/2026 | By News Bureau
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
Drug Discovery & Development | 19/01/2026 | By News Bureau
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Drug Discovery & Development | 19/01/2026 | By News Bureau
Russian Scientists Develop Chemical Method to Boost Anti-Cancer Drug Potency
Researchers in Russia have developed a novel chemical method that could significantly enhance the effectiveness of anti-cancer medicines, offering new momentum to oncology drug development.
Drug Discovery & Development | 16/01/2026 | By Darshana
US FDA Delays Two Drug Reviews Under New Priority Voucher Program
The U.S. Food and Drug Administration (FDA) has delayed the review of two medicines selected under its recently launched Commissioner’s National Priority Voucher Program, after regulators raised concerns related to safety and clinical effectiveness.
Drug Discovery & Development | 16/01/2026 | By Darshana | 203
J&J's Tecvayli Cuts Death Risk in Phase III Multiple Myeloma Study
Phase III MajesTEC-9 shows Tecvayli significantly improves survival, reducing progression or death risk by 71 percent versus standard care in relapsed multiple myeloma.
Drug Discovery & Development | 15/01/2026 | By News Bureau
European Commission Approves Teizeild to Delay Onset of Type 1 Diabetes
Teizeild (teplizumab) becomes the first disease-modifying therapy approved in the EU to delay progression to stage III type 1 diabetes in eligible adults and children aged eight and above.
Drug Discovery & Development | 13/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy